MeDirect

The chart shows the growth of an initial investment of €10,000 in MeDirect, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every year.

Based on dividend-adjusted daily data since Nov 2, 2023, MeDirect's average daily return is +0.12%, while the average monthly return is +2.53%. At this rate, an investment would double in approximately 2.3 years.

Historically, 80% of months were positive and 20% were negative. The best month was Sep 2025 with a return of +11.3%, while the worst month was Mar 2026 at -10.2%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 1 months.

On a daily basis, MeDirect closed higher 57% of trading days. The best single day was Apr 10, 2025 with a return of +4.4%, while the worst single day was Apr 4, 2025 at -5.8%.

MeDirect has an annualized alpha of 28.23%, beta of 0.28, and R² of 0.07 versus S&P 500 Index. Calculated based on daily prices since November 02, 2023.

• This portfolio captured 93.42% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -43.91%) — a profile typical of hedging or uncorrelated assets.
• Beta of 0.28 may look defensive, but with R² of 0.07 this portfolio is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this portfolio's risk.
• R² of 0.07 means this portfolio moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

MeDirect has an expense ratio of 0.26%, which is considered low. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

MeDirect ranks 52 for risk / return — on par with similar portfolios. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

MeDirect Sharpe ratios as of Apr 15, 2026 (values are recalculated daily):

• 1-Year: 2.65
• All Time: 1.96

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

Compared to the broad market, where average Sharpe ratios range from 2.15 to 2.98, this portfolio's current Sharpe ratio falls between the 25th and 75th percentiles. This indicates that its risk-adjusted performance is in line with the majority of portfolios, suggesting a balanced approach to risk and return—likely suitable for a wide range of investors.

The chart below shows the rolling Sharpe ratio of MeDirect compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the MeDirect. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the MeDirect was 14.89%, occurring on Apr 7, 2025. Recovery took 40 trading sessions.

The current MeDirect drawdown is 4.41%.

The chart below shows the rolling one-month volatility.